Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 36Colonic Neoplasms 10Rectal Neoplasms 8Neoplasm Metastasis 8Neoplasms 5Pancreatic Neoplasms 2Carcinoma, Neuroendocrine 2Adenocarcinoma 2Stomach Neoplasms 1Ras-mutated Metastatic Colorectal Cancer 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Metastatic Pancreatic Ductal Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1Liver Metastasis Colon Cancer 1Gastrointestinal Neoplasms 1Exanthema 1Carcinoma, Basal Cell 1Carcinoma 1CRC 1Advanced Cancer 1

Interventions

Bevacizumab 2regorafenib 1Oxaliplatin 1IFL protocol 1FOLFOXIRI protocol 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liver Metastasis Colon Cancer × IFL protocol × Clear all
NCT04003792 2020-10-20

Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.

Rabin Medical Center

Phase 2 Unknown
49 enrolled
Gastrointestinal

Liver Metastasis Colon Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡